Drugs / Nordihydroguaiaretic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00678015 | May 2008 → Feb 2011 | prostate cancer | University of California, San Francisco | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nordihydroguaiaretic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00678015 ↗ |
| Known as | NDGA | “Nordihydroguaiaretic Acid (NDGA)” NCT00678015 ↗ |
| Action | Inhibit | “NDGA, a small molecule inhibitor of the IGF-1R” PMID 21971890 ↗ Oct 2011 |
| Modality | Small molecule | “NDGA, a small molecule inhibitor of the IGF-1R” PMID 21971890 ↗ Oct 2011 |
| Route | Oral | “NDGA 2000 mg was given orally daily” PMID 21971890 ↗ Oct 2011 |
| Target | IGF1R | “NDGA, a small molecule inhibitor of the IGF-1R” PMID 21971890 ↗ Oct 2011 |